Haleon Sells Its Nicotine Replacement Therapy Business Outside Of The U.S. To Dr. Reddy's Laboratories SA For Total Consideration Of £500 Million
Portfolio Pulse from Benzinga Newsdesk
Haleon has agreed to sell its nicotine replacement therapy business outside of the U.S. to Dr. Reddy's Laboratories for £500 million.
June 26, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Haleon is selling its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories for £500 million.
The sale of the nicotine replacement therapy business will provide Haleon with significant capital, which could be used for other strategic initiatives or to strengthen its balance sheet. This is likely to be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Dr. Reddy's Laboratories is acquiring Haleon's nicotine replacement therapy business outside the U.S. for £500 million.
The acquisition of Haleon's nicotine replacement therapy business will expand Dr. Reddy's product portfolio and market reach, which is likely to be seen as a positive development by investors.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100